Objective: Transcatheter aortic valve implantation (TAVI) has shown promising results in patients with severe aortic stenosis (AS) at high risk for open heart surgery. We aimed to evaluate outcomes of patients who underwent TAVI with Edwards SAPIEN 3 Transcatheter Heart Valve (S3), a secondgeneration TAVI device.
T ranscatheter aortic valve implantation (TAVI) has become the therapy of choice for severe, symptomatic aortic stenosis (AS) in inoperable patients, and is non-inferior to surgical aortic valve replacement (sAVR) in high-risk patients. [1] [2] [3] [4] The procedure was first performed in 2002. [5] Since then, this technology has evolved profoundly. At present, primary issues related to TAVI that remain to be solved are high incidence of paravalvular aortic regurgitation (PAR), peripheral vascular complications, and need for permanent pacemaker implantation (PPI). So far, new types of transcatheter bioprosthetic valves have been the means to try to resolve these problems. Ideal aortic bioprosthesis must be durable and reduce risk of complications.
Edwards SAPIEN 3 Transcatheter Heart Valve (S3) (Edwards Lifesciences, Inc., Irvine, CA, USA) is newest generation of balloon-expandable valve. It obtained CE mark approval on January 27, 2014 and is commercially available in Europe. It incorporates a number of new and enhanced features intended to reduce risk of vascular injury and PAR, as well as to facilitate rapid and accurate deployment. Significant design improvements have been incorporated when compared with earlier SAPIEN XT valve. Lower profile delivery systems were introduced to enable less traumatic implantation via transfemoral, transapical, and transaortic access routes. More importantly, these changes were designed to facilitate percutaneous access and closure even in patients with smaller iliofemoral arteries.
The aim of this single-center study was to report outcomes of TAVI with S3 valve, which was designed to decrease major vascular complications, rate of paravalvular leak and to enhance valve positioning.
METHODS

Patient population
Of 294 patients, we prospectively included 31 patients who underwent TAVI with S3 valve system between November 2014 and June 2016 at our facility. Before the procedure, multi-modal cardiovascular imaging, including transthorasic echocardiography (TTE) and transesophageal echocardiography, cardiac and peripheral multi-slice computed tomography angiography (CTA), and invasive coronary and peripheral angiography, were performed on all patients. Cardiac CTA was especially important for accurate assessment of aortic valve anatomy and calcification, aortic annular sizing, subannular calcification, aortic root size and geometry, height of coronary ostia and septal bulging from aortic annular plane, and final valve sizing. Invasive coronary angiography was also important for preoperative assessment and determination of optimal position of aortic root during procedure. Invasive peripheral angiography was performed for accurate estimation of access site to ensure safe and successful procedure. TTE was performed just after procedure and again before hospital discharge. Decision to proceed with TAVI was made by multidisciplinary heart team, which included cardiovascular surgeons, invasive cardiologists, and anesthesiologists. Eligibility was based on calculated surgical risk scores (European System for Cardiac Operative Risk Evaluation [EuroSCORE] and the Society of Thoracic Surgeons [STS] risk score), other clinical (e.g., frailty) and technical issues (e.g., porcelain aorta, adherent bypass grafts). Written, informed consent was obtained from all patients and the present study was approved by Atatürk Training and Research Hospital ethics committee.
Transcatheter aortic valve implantation
All TAVI procedures were performed in catheterization laboratory under fluoroscopic guidance by dedicated team of invasive cardiologists, cardiovascular surgeons, and anesthesiologists. Depending on the patient's clinical condition and evaluation of the anesthesiologist, procedure was performed under general anesthesia or local anesthesia with mild sedation. Only device implanted was balloon-expandable S3 pericardial bioprosthesis. All patients had transvenous temporary cardiac pacing during procedure. Transfemoral route was used when feasible; alternatively trans-subclavian route was used. All trans-subclavian procedures were performed using surgical cutdown technique. In transfemoral procedures, however, per- Adjunctive pharmacological therapy consisted of heparin during the procedure (activated clotting time between 250-300 s), acetylsalicylic acid (100 mg/d) indefinitely, and clopidogrel (75 mg/d) for 6 months after procedure.
Statistical analysis
Statistical analysis was performed using SPSS software, version 17.0 (IBM Corp., Armonk, NY, USA). Continuous variables were presented as mean (range) ± 1 SD. Discrete variables were expressed as count and percentage. Categorical variables were compared using Pearson's chi-squared test. Statistical significance was defined as p value <0.05.
RESULTS
Total of 294 patients underwent TAVI between July 2011 and June 2016; 31 patients who received second-generation S3 valve were included in the present study. Baseline clinical characteristics of the study population are presented in Table 1 . Mean age was 76.1±12.6 years (range: 57-100 years) and 14 were observed during or after the procedure in any patient. Permanent pacemaker was implanted in 2 (6.4%) patients due to development of complete atrioventricular (AV) block (n=1) and asystole (n=1) just after valve deployment. In-hospital death occurred in 1 patient (3.2%) due to acute pulmonary edema, not valve dysfunction or other procedure-related problem. Investigation of clinical and procedural features of this patient revealed previous history of CABG and severe HF (LVEF: 20%). Patient had received 29-mm bioprosthesis through transfemoral route and PPI was performed during procedure due to development of complete AV block.
Post-TAVI aortography and TTE were utilized to evaluate degree of PAR. Pigtail catheter was placed over bioprosthetic valve and post-TAVI aortography was performed with 20 cc opaque contrast agent delivered under 800 pci within 1.5 seconds at prime position. Hemodynamic data were obtained immediately post-TAVI, including measurement of LV endfemale (45.1%). All patients had severe symptomatic AS with mean gradient of 49.0±13.4 mmHg and mean aortic valve area of 0.67±0.11 cm². There was severe systolic heart failure (HF) (left ventricle ejection fraction [LVEF] <30%) in 4 patients. Two patients with severe HF were diagnosed as having low flow-low gradient severe AS after dobutamin stress echocardiography. Mean body mass index (BMI) was 27.4±5.9 kg/m². One patient was morbidly obese with BMI of 52 kg/m². Mean logistic EuroSCORE was 31.4±17.7% and mean STS risk score was 7.8±3.1%. All patients but 3 had New York Heart Association (NYHA) class III or IV dyspnea. Rate of coronary artery disease was very high (n=24, 77.4%), with prior percutaneous coronary intervention in 11 (35.4%) and prior coronary artery bypass grafting (CABG) in 11 (35.4%) patients. Previous ischemic stroke was present in 3 patients: 1 transient ischemic attack (TIA) and 2 with major stroke and sequelae. There was chronic renal failure in 12 (38.7%) patients (1 in dialysis treatment for 4 years), with estimated glomerular filtration rate below 60 mL/min. Furthermore, there was history of Hodgkin's lymphoma and rectal carcinoma in 2 separate patients, both of whom were cured with chemotherapeutic drugs and surgery.
Procedural data of study patients is provided in Table 2. S3 valve was implanted in 27 (87.1%) patients via transfemoral access and in 4 (12.9%) patients via trans-subclavian access. Local anesthesia with mild sedation was used for 29 (93.6%) patients and general anesthesia was used for remaining 2 (6.4%) patients. In 7 (22.6%) patients, 23-mm prosthesis was implanted, while 26-mm prosthesis was used for 16 (51.6%) patients and 29-mm prosthesis for 8 (25.8%) patients. A 14-F sheath was used for 23-mm and 26-mm bioprostheses and 16-F sheath was used for 29-mm bioprostheses. Aortic balloon valvuloplasty was performed before valve deployment. For access site closure, percutaneous (n=27, 87.1%) or surgical cutdown (n=4, 12.9%) techniques were used. ProStar (n=2, 7.4%) or double Perclose ProGlide (n=25, 92.6%) vascular devices were used for percutaneous closure. Mean procedural time was 43.4±6.7 minutes. Mean quantity of contrast material used during procedure was 79.5±39.7 mL.
Procedural outcomes can be seen in Table 3 . All patients were successfully treated with S3 valve; procedural success rate was 100%. No stroke or TIA was diastolic pressure and diastolic pressure, and were compared with pre-TAVI values, as in other studies. [6] There was none to trace quantity of PAR in 29 patients (93.6%) and mild PAR in 2 patients (6.4%).
There was no more than mild PAR in any patient. TTE confirmed this result. Mean transaortic gradient was reduced from 49.0±13.4 mmHg to 11.4±5.7 mmHg and mean aortic valve area increased from 0.67±0.11 cm² to 1.7±0.5 cm² at discharge. When LVEF measurements from before and after procedure were compared, mild increase (53.0±12.0% vs 57.6±10.8%, respectively) was observed. Mean intensive care unit stay was 2.1±1.2 days and mean hospital stay was 5.8±1.8 days.
DISCUSSION
This is the first study in Turkey to report outcomes of TAVI performed with S3 valve system at a single center. Implantation with new, low-profile, balloonexpandable S3 valve system was successful in all patients. Clinical and hemodynamic outcomes were also excellent.
TAVI is well-established therapeutic option for severe degenerative AS in patients with high surgical risk. [7] Since first TAVI procedure in 2002, significant advances have been made in device technology, appropriate patient and valve selection, procedural technique, and post-procedural management. Placement of Aortic Transcatheter Valves (PARTNER) trial determined superiority of TAVI to medical treatment and non-inferiority to sAVR.
[2] US CoreValve Pivotal Trial High Risk Study demonstrated better survival at 1 year with TAVI compared to sAVR. [4] However, despite these encouraging results, first-generation TAVI devices have several limitations, with post-procedural aortic regurgitation (AR) being one of the primary concerns. [8] Major advantages of S3 valve are its lower profile, facilitated positioning, and paravalvular seal- after TAVI. The large observational United Kingdom Transcatheter Aortic Valve Implantation Registry (UK TAVI) [13] and the French Aortic National CoreValve and Edwards (FRANCE 2) [14] registry reported need for new pacemaker rate at 24.4% and 24.2%, respectively, with CoreValve (Medtronic, Inc., Minneapolis, Minnesota) device versus 7.4% and 11.5%, respectively, with SAPIEN XT valves. In PARTNER trial, [15] prior permanent pacemaker (PPM), new PPM, and chronic left bundle branch block (LBBB) patients had worse clinical and echocardiographic outcomes compared with non-PPM patients, and presence of PPM was independently associated with 1-year mortality. Thus, reducing need for PPI as a specific aspect of clinical outcome after TAVI is of significant importance. Emerging data indicate rate of 13% to 30% PPI after TAVI with S3 valve. [16] [17] [18] Husser et al. [19] also reported rate of 12% PPI after S3 valve implantation. Interestingly, in our study, only 2 patients (6.4%) required new pacemaker, and S3 device did not result in higher rate of PPI during hospitalization.
In the present study, there was only 1 in-hospital death. Evaluation of this case revealed very high-risk patient with history of severe heart failure (LVEF of 20%), CABG (with left internal mammarian artery to left anterior descending artery graft), insulin-dependent diabetes mellitus, hypertension, and carotid artery disease (with history of endarterectomy). He received PPI during TAVI procedure due to development of complete AV block. In addition, LBBB was observed on electrocardiography and he received 29-mm S3 valve, both of which are thought to be indicator of high risk for new PPI.
Study limitations
Main limitation of the present study is sample size. Number of patients included in this study may prevent generalization of these results. However, all 31 patients underwent TAVI performed by the same heart team at highly experienced TAVI center after evaluation using multimodal imaging techniques.
Conclusion
Lower rate of PAR, peripheral vascular complications, and PPI were found compared with data from other clinics performing TAVI with S3 valves. This second-generation valve had high rate of device success. Therefore, we may conclude that S3 valve can be used confidently in all TAVI procedures. ing cuff preventing PAR. Moreover, low-profile delivery system reduces potential vascular complications.
PAR after TAVI has been found to be associated with increased mortality rate. [9] Negative prognostic impact of post-procedural AR on patients undergoing TAVI has been extensively reported. In particular, occurrence seems to be associated with two-to threefold increase in 30-day and 1-year mortality. [8] Post-procedural AR was significant limitation of first-generation TAVI devices. [8] Therefore, new devices like S3 valve that can prevent or reduce rate of PAR were introduced into clinical practice. Binder et al. [10] reported none to trivial PAR in 73% of 15 patients who underwent TAVI with S3 valve and only mild PAR in the remainder. In the present study, PAR was absent or trivial in 93.6% of patients and mild in the rest. Most likely reasons for this lower rate of PAR are 1) outer skirt, which enhances paravalvular seal; 2) accurate positioning; 3) precise sizing with multi-modal imaging; and 4) proper patient selection. In this study, S3 valve was chosen especially for patients with high risk of PAR, including patients with bulky aortic calcification.
Vascular complications have been the most common cause of morbidity and mortality after TAVI. [1, 11] Ratio of outer diameter of sheath to minimal lumen diameter of artery used for access site is strong predictor of vascular complications. [11] S3 valve system can be introduced with lower profile delivery system using 14-F and 16-F sheaths and therefore might facilitate transfemoral TAVI in patients previously considered unsuitable for femoral artery route. [12] In present study, TAVI with S3 valve was performed on 2 patients via transfemoral access after simultaneous common iliac artery stenting. There was no minor or major vascular complication in our study, consistent with reported results of Binder et al. [10] Absence of vascular complications can be explained by deployment of S3 valve with lower profile delivery system in addition to significant experience of our center.
Length of S3 valve is slightly greater than earlier SAPIEN and SAPIEN XT valves. Although difference is not large, this increase seems to facilitate optimal positioning within the native aortic valve and annulus. However, by potentially extending area of contact with the septum, increased size of valve might increase risk of AV block and thus, need for PPI. Complete AV block necessitating PPI is a major concern
